| DB ID | MyCo_2346 |
| Title | Detection of Rhizopus-specific antigen in human and murine serum and bronchoalveolar lavage |
| Year | 2020 |
| PMID | 32060526 |
| Fungal Diseases involved | Mucormycosis |
| Associated Medical Condition | None |
| Genus | None |
| Species | None |
| Organism | None |
| Ethical Statement | The experimental protocol was approved by the Animal Experiment Ethics Committee of Osaka City University, Japan. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | bronchoalveolar lavage fluid (BALF) |
| Host Group | Animal |
| Host Common name | Mice |
| Host Scientific name | Mus musculus |
| Biomarker Name | RSA-specific rabbit monoclonal antibodies |
| Biomarker Full Name | Rhizopus-specific antigen (RSA)-specific rabbit monoclonal antibodies |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Japan |
| Cohort | For examinations, mice were euthanized on days 1 to 4. On day 1, 5 control mice and 5 inoculated mice were euthanatized, on day 2, 3, 4, and 5 inoculated mice were euthanized. |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Mucormycosis is an infection caused mainly by fungi, such as Rhizopus, Mucor, Rhizomucor, Lichtheimia, and Cunninghamella, which are widely found in the soil and on the surface of plants. Cases of mucormycosis are classified into six groups depending on the site of infection, namely, nasal cerebral, pulmonary, gastrointestinal, cutaneous, disseminated, and uncommon. Although mucormycosis is extremely rare in humans with normal immunity levels, it results in poor prognosis in immunocompromised patients, making it an important disease. Pulmonary mucormycosis occurs most frequently in patients with hematological malignancy. In order to improve its prognosis, treatment with single or multidrug combination antifungal agents, surgical removal of the lesion, and amelioration of the immunosuppressive state are necessary. Delayed diagnosis and treatment doubles the mortality compared to that associated with early treatment, which is especially important in patients with hematological malignancies. Thus, there is a need to develop early detection systems to improve the prognosis. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | ELISA, Immunohistochemistry |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
